Central levodopa influx and the clinical motor response to levodopa in patients with parkinson disease complicated with motor fluctuations and dyskinesias

Clinical Neuropharmacology

Volumn 32, Issue 6, 2009, Pages 321-325

  López Ariztegui, Nuria ^a,b   Arévalo, María Angeles ^c,d   De Ceballos, Maria L ^c,d   Grandas, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c INSTITUTO CAJAL   (Spain)

^d CSIC   (Spain)

Author keywords

Central influx; Dyskinesias; Fluctuations; Levodopa; Parkinson

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; MALE; MATHEMATICAL ANALYSIS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPARKINSON AGENTS; BRAIN; CARBIDOPA; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 74249104164     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181b40378     Document Type: Article

References (27)

1. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology 1980;24:431-441.
2. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376. (Pubitemid 17053274)
3. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989;39(suppl 2):11-19.
4. Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
5. Marconi R, Lefebre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease, phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
6. Cubo E, Gracies JM, Benabon R, et al. Early morning off-medication dyskinesias, dystonia and choreic subtypes. Arch Neurol 2001;58: 1379-1382.
7. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
8. Nutt JG, Holdorf NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39: 561-573.
9. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
10. Holdorf NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-453.
11. Contin M, Riva R, Martinelli P, et al. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-371.
12. Wade LA, Katzman R. Synthetic amino acids and the nature of L-dopa transport at the blood-brain barrier. J Neurochem 1975;25:837-842.
13. Pardridge WM. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J Neurochem 1977; 28:103-108.
14. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
15. Leenders KI, Poewe WH, Palmer AJ, et al. Inhibibion of (18F)fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258-262.
16. Wagner J, Vitali P, Palfreyman MG, et al. Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3- methoxyphenylalanine, norepinephrine, 3, 4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high-performance liquid chromatography with electrochemical detection. J Neurochem 1982;38:1241-1254.
17. Joseph MH, Davies P. Electrochemical activity of o-phthalaldehyde- mercaptoethanol derivatives of amino acids. Application to high-performance liquid chromatographic determination of amino acids in plasma and other biological materials. J Chromatogr 1983;277:125-136.
18. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-and intrarater reliability assessment. Mov Disord 1994;9:390-394.
19. Pardrigde WM, Olendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochem Biophys Acta 1975;401:128-136.
20. Ito H, Ota M, Seki C, et al. Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[A-11C] DOPA. Nucl Med Commun 2006;27:723-731.
21. De la Fuente-Fernández R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
22. Guttman M, Leger G, Cedarbaum J, et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992;31:638-643.
23. Torstenson R, Hartvig P, Langstrom B, et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997;41:334-340.
24. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(suppl 2):25-38.
25. Verhagen Metman L, van den Munckhof P, Klaassen AA, et al. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 1997;49:711-713.
26. Nutt JG, Carter JH, Lea ES, et al. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002;51:686-693.
27. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246:1127-1133.